Splosna Bolnisnica Celje
- Address
- lock Available on a paid plan
Digestive System Diseases and Immune System Diseases
At Splosna Bolnisnica Celje, clinical research in Digestive System Diseases and Immune System Diseases focuses on inflammatory bowel conditions, especially Moderate to Severe Crohn’s Disease and Ulcerative Colitis. These studies are designed to evaluate new and existing therapies for controlling symptoms, reducing inflammation, and improving patient outcomes.
- Testing targeted therapies for Crohn’s Disease
- Comparing treatment options for ulcerative colitis
- Assessing safety, efficacy, and disease control in chronic intestinal inflammation
The work at this site reflects a strong interest in improving care for people living with long-term digestive and immune-related disorders.
Cardiovascular Diseases
Research in Cardiovascular Diseases at this hospital centers on major conditions such as Atherosclerotic cardiovascular disease and Heart failure. The trials aim to determine whether new treatment approaches can better prevent serious events and support patients with established heart disease.
- Evaluating therapies to lower the risk of heart attack and stroke
- Studying treatments for people with heart failure
- Measuring whether novel medicines improve long-term cardiovascular outcomes
These studies highlight a focus on both prevention and treatment in serious circulatory disorders.
Nervous System Diseases
Clinical trials in Nervous System Diseases are addressing Multiple Sclerosis, with an emphasis on finding better ways to reduce relapses and manage disease activity. The research is aimed at improving treatment effectiveness while maintaining safety for people living with this chronic neurological condition.
- Comparing therapies for relapsing multiple sclerosis
- Assessing whether newer medicines can reduce relapse frequency
- Supporting safer and more effective long-term disease control
This area adds important neurological research to the site’s broader clinical portfolio.
Skin and Connective Tissue Diseases
In Skin and Connective Tissue Diseases, the site is studying Hidradenitis Suppurativa, a painful inflammatory skin condition that can be difficult to manage. The trials are focused on easing signs and symptoms and improving quality of life for adolescents and adults affected by this disease.
- Evaluating new options for hidradenitis suppurativa
- Looking at symptom relief and disease improvement
- Assessing whether emerging therapies offer better control of inflammation
These studies show an interest in immune-driven skin disease alongside other inflammatory conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 29 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG4trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 25 other sites in Slovenia
Therapeutic Area Benchmark — Slovenia
Select a therapeutic area to compare against other sites in Slovenia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovenia
Market Share
Country: Slovenia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Splosna Bolnisnica Celje
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized Study of Andexanet Alfa Compared to Usual Care in Patients Receiving a Factor Xa Inhibitor who Require Urgent Surgery or Procedure (ANNEXA-RS) | AstraZeneca AB | Phase III | Not Recruiting | — | Jun 2024 |
IMP list
lock Showing 1 of 29 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Lutikizumab | 3 | Unknown | 2024-08-19 | 2024-12-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.